Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CELU 
Celularity Inc (CELU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: CELU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.1% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.25M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 1 | Beta 0.76 | 52 Weeks Range 1.00 - 4.35 | Updated Date 10/27/2025 |
52 Weeks Range 1.00 - 4.35 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-10-14 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin -165.21% | Operating Margin (TTM) -276.57% |
Management Effectiveness
Return on Assets (TTM) -23.14% | Return on Equity (TTM) -6367.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 123741613 | Price to Sales(TTM) 1.24 |
Enterprise Value 123741613 | Price to Sales(TTM) 1.24 | ||
Enterprise Value to Revenue 2.78 | Enterprise Value to EBITDA -36.78 | Shares Outstanding 26691477 | Shares Floating 14498010 |
Shares Outstanding 26691477 | Shares Floating 14498010 | ||
Percent Insiders 39.9 | Percent Institutions 13.29 |
Upturn AI SWOT
Celularity Inc
Company Overview
History and Background
Celularity Inc. was founded in 2016. It focuses on placental-derived cell therapies. It went public via SPAC GX Acquisition Corp. in 2021. Milestones include developing multiple allogeneic cell therapy platforms and advancing clinical trials in various indications.
Core Business Areas
- Allogeneic Cell Therapy: Develops and manufactures off-the-shelf cell therapies derived from the placenta to treat diseases across hematology-oncology, immunology, and degenerative diseases.
- Biomanufacturing: Offers biomanufacturing services, including cell and gene therapy manufacturing, to other companies.
Leadership and Structure
Robert J. Hariri, M.D., Ph.D. is the Founder, Chairman, and CEO. The company has a typical corporate structure with departments for R&D, manufacturing, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- CYNK-001: An off-the-shelf NK cell therapy targeting hematologic malignancies and solid tumors. Market share data is not publicly available. Competitors include Fate Therapeutics (FATE), NantKwest (now ImmunityBio - IBRX), and others developing NK cell therapies.
- PDA-002: A placental-derived cell therapy for Crohn's disease. Market share data is not publicly available. Competitors include Takeda (ENTYVIO), Janssen (STELARA), and AbbVie (HUMIRA) who provide drug for Crohn's disease.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advances in regenerative medicine and immunology. It is characterized by intense competition and high regulatory hurdles.
Positioning
Celularity is positioned as a leader in placental-derived cell therapies, leveraging its proprietary technology platform. Its competitive advantage lies in its allogeneic approach, which allows for off-the-shelf availability.
Total Addressable Market (TAM)
The total addressable market for cell therapies is estimated to be in the tens of billions of dollars. Celularity is focusing on specific indications within this broader market, aiming to capture a significant share.
Upturn SWOT Analysis
Strengths
- Proprietary placental-derived cell therapy platform
- Allogeneic approach for off-the-shelf availability
- Experienced leadership team
- Biomanufacturing capabilities
Weaknesses
- Limited clinical trial data
- High cash burn rate
- Dependence on external funding
- Relatively small market capitalization
Opportunities
- Expanding clinical trials to new indications
- Partnerships with pharmaceutical companies
- Increasing awareness of cell therapies
- Potential for FDA approvals
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Funding constraints
Competitors and Market Share
Key Competitors
- FATE
- IBRX
- CRIS
Competitive Landscape
Celularity faces competition from larger, more established companies with greater resources. Its advantage lies in its placental-derived cell therapy platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by pipeline development and clinical trial progress.
Future Projections: Future growth is projected based on analyst estimates. Revenue growth is expected as products move closer to commercialization.
Recent Initiatives: Recent initiatives include advancing clinical trials for CYNK-001 and PDA-002 and expanding biomanufacturing capabilities.
Summary
Celularity is a cell therapy company focused on placental-derived products with potential in oncology and inflammatory diseases. Its allogeneic approach offers a competitive advantage, but the company faces challenges with clinical trials, funding, and competition. Positive clinical results and strategic partnerships are crucial for future success. Cash burn is a concern. It is a high risk, high reward company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celularity Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-08-08 | Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.celularity.com |
Full time employees 123 | Website https://www.celularity.com | ||
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.